Highlights
- Fiscal 2026 Revenue was USD 364,777 against USD 110,459 in fiscal 2025.
- The net loss was USD 3,095,838, or USD 0.63 per share.
- Cash and cash equivalents were USD 2,298,809 at June 30, 2026.
- The auditor's report states substantial doubt about continuing as a going concern.
Amesite Inc. (NASDAQ:AMST) shares were trading near their all-time low at USD 0.5312 on November 6, 2026, down 1.17% on the day. The company reported fiscal 2026 revenue of USD 364,777 and a net loss of USD 3,095,838 for the year ended June 30, 2026.
Amesite builds and commercializes artificial intelligence-powered solutions for the enterprise and for professionals, with particular emphasis on the post-acute healthcare market. In fiscal 2026 it launched a census-based Enterprise tier with electronic medical records integration.
Annual Results
Net revenue was USD 364,777 against USD 110,459 for the year ended June 30, 2025. The filing states that revenue was primarily B2B license fee revenue related to the NurseMagic app.
Total operating expenses were USD 3,507,883 against USD 3,714,072. The loss from operations was USD 3,143,106 against USD 3,603,613. The net loss was USD 3,095,838 against USD 3,617,086, and the basic and diluted loss per share was USD 0.63 against USD 1.03.
Balance Sheet and Cash Flow
Cash and cash equivalents were USD 2,298,809 at June 30, 2026, against USD 2,333,418 a year earlier. Total Assets were USD 3,029,637 against USD 3,097,099, and total stockholders' Equity was USD 2,653,719 against USD 2,738,503.
The accumulated Deficit was USD 44,546,425 against USD 41,450,587. Net cash used in Operating Activities was USD 2,146,717 against USD 2,455,248.
Going Concern
The auditor's report notes that the company has suffered recurring losses from operations and negative cash flows from operating activities, which raises substantial doubt about its ability to continue as a going concern. The financial statements were prepared on a Going Concern basis.
In its discussion of results, management states that it is not currently profitable and cannot provide any assurance that it will ever be profitable.
Share Count
There were 6,549,851 shares of common stock outstanding on September 23, 2026. The filing reports that the Market Value held by non-affiliates on December 31, 2025 was approximately USD 8,995,000.
Management evaluated events through September 23, 2026 for recognition or disclosure and the filing describes no further subsequent events in its notes.
Products and Customers
The company operates through two product lines. NurseMagic includes a business-to-business enterprise application and a business-to-consumer solution for individual healthcare professionals. LynkMagic provides enterprise artificial intelligence solutions for healthcare and related organizations.
In fiscal 2026, Amesite introduced the AI-native NurseMagic electronic medical records capability and secured its largest enterprise deployment to date, serving an approximately 2,700-patient census. The new Enterprise tier is census-based and adds automated interdisciplinary team reporting and configurable documentation.
Corporate Background
The company was incorporated in November 2017 and is listed on the Nasdaq Capital Market under the symbol AMST. On September 18, 2020, it completed a reorganizational Merger under a merger agreement dated July 14, 2020.
Net cash used in operating activities of USD 2,146,717 compares with cash and cash equivalents of USD 2,298,809 at year end. The filing's Liquidity discussion and the auditor's going concern paragraph should be read together.






Please wait processing your request...